Acquisitions

Acquisitions completed from the 2022 financial year are distributed among the group’s business areas as follows:

During the interim period, one acquisition has been completed.

On September 1 2023, AddLife acquired all shares in the company Emmat Medical Ltd for the Medtech business area. Emmat is active in surgical products in Great Britain and has a turnover of approximately SEK 28 m and has four employees. The company is integrated into the Healthcare 21 Group.

Revaluation of liabilities for contingent considerations regarding previous acquisitions has resulted in income of SEK 100 m of which SEK 82 m relates to the acquisition of AddVision and SEK 15 m relates to the acquisition of Bio-Connect. During the interim period, this has been reversed and reported in other operating income. Contingent considerations amounted to SEK 16 m have been paid during the interim period regarding Ropox, which was acquired in 2020.